scholarly journals Transcranial direct current stimulation improves myofascial pain syndrome and chronic fatigue

Reumatismo ◽  
2020 ◽  
Vol 72 (3) ◽  
pp. 186-188
Author(s):  
R.G. Misse ◽  
A.M. Dos Santos ◽  
J.M. De Souza ◽  
S.K. Shinjo
Keyword(s):  
Direct Current ◽  
Transcranial Direct Current Stimulation ◽  
Myofascial Pain ◽  
Pain Syndrome ◽  
Myofascial Pain Syndrome ◽  
Chronic Fatigue ◽  
Direct Current Stimulation

Not available.

scholarly journals Pain Reduction in Myofascial Pain Syndrome by Anodal Transcranial Direct Current Stimulation Combined With Standard Treatment

2014 ◽  
Vol 30 (12) ◽  
pp. 1076-1083 ◽  
Author(s):  
Piyaraid Sakrajai ◽  
Taweesak Janyacharoen ◽  
Mark P. Jensen ◽  
Kittisak Sawanyawisuth ◽  
Narong Auvichayapat ◽  
...  
Keyword(s):  
Direct Current ◽  
Transcranial Direct Current Stimulation ◽  
Standard Treatment ◽  
Myofascial Pain ◽  
Pain Syndrome ◽  
Myofascial Pain Syndrome ◽  
Pain Reduction ◽  
Direct Current Stimulation

scholarly journals Transcranial Direct Current Stimulation of the Occipital Cortex in Medication Overuse Headache: A Pilot Randomized Controlled Cross-Over Study

2020 ◽  
Vol 9 (4) ◽  
pp. 1075 ◽  
Author(s):  
Anthony G. Mansour ◽  
Rechdi Ahdab ◽  
Georges Khazen ◽  
Christelle El-Khoury ◽  
Toni M. Sabbouh ◽  
...  
Keyword(s):  
Direct Current ◽  
Transcranial Direct Current Stimulation ◽  
Medication Overuse ◽  
Medication Overuse Headache ◽  
Pain Syndrome ◽  
Occipital Cortex ◽  
Daily Consumption ◽  
Direct Current Stimulation ◽  
Frequent Use ◽  
Age Range

Background: Medication overuse headache (MOH) is a chronic pain syndrome that arises from the frequent use of acute antimigraine drugs. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique with a possible therapeutic effect in this particular context. Methods: This was a randomized, sham-controlled, cross-over study. Eighteen patients with MOH (17 women, age range: 20–38 years) received three sets of three consecutive daily sessions of tDCS: anodal tDCS over the prefrontal cortex, cathodal tDCS over the occipital cortex ipsilateral to the dominant side of migraine pain, and sham. The order in which the tDCS blocks were delivered was randomly defined based on a 1:1:1 ratio. Patients filled in a migraine diary that allowed recording of the pain intensity (visual analogue scale) and the daily consumption of analgesic pills from one week before to two weeks after each condition. Results: Both prefrontal and occipital tDCS lowered the total number of migraine days and the number of severe migraine days per week at week 1, but only the effects of occipital tDCS on these two outcomes lasted until week 2. Only occipital tDCS decreased the daily analgesic pills consumption, at weeks 1 and 2. Conclusion: Three consecutive days of cathodal occipital tDCS appear to improve the clinical outcomes in patients with MOH.

scholarly journals Transcranial direct current stimulation (a-tCDS) after subacromial injections in patients with subacromial pain syndrome: a randomized controlled pilot study

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Samuel Larrivée ◽  
Frédéric Balg ◽  
Guillaume Léonard ◽  
Sonia Bédard ◽  
Michel Tousignant ◽  
...  
Keyword(s):  
Pilot Study ◽  
Direct Current ◽  
Transcranial Direct Current Stimulation ◽  
Repeated Measures ◽  
Symptomatic Relief ◽  
Pain Syndrome ◽  
Control Group ◽  
Significant Group ◽  
Direct Current Stimulation ◽  
Subacromial Pain Syndrome

Abstract Background Subacromial pain syndrome (SAPS) is a common complaint in orthopaedics. Subacromial corticosteroid injections (CSI) can relieve pain in the short term. Anodal transcranial direct current stimulation (a-tDCS) has been used for symptomatic pain relief in a variety of chronic pain conditions. The aim of this pilot study was to assess whether the application a-tDCS could enhance the symptomatic relief provided by CSI in patients affected by SAPS. Methods Thirty-eight participants (18 to 65-year-old) suffering from SAPS were recruited to have a CSI and randomly allocated to receive, 1 weeks post CSI, real a-tDCS (r-tDCS), sham tDCS (s-tDCS) or no intervention (Control). Upper limb function was measured 1 week prior to the CSI, at the 2- and 4-week follow-ups using self-administered questionnaires and physical measures. Self-reported pain and activity during each day were logged by the participants using visual analog scales (VAS). Differences between groups were tested using repeated-measures ANOVAs. Results Pain VAS and the Single Assessment Numeric Evaluation scale (SANE) showed significant improvement from baseline 2 weeks and 4 weeks after CSI in all groups (p < 0.05). There were no significant group X time interaction 2 weeks following tDCS treatment in any of the variables. Conclusion All groups showed significant improvement in pain VAS and SANE scores following the CSI. One session of a-tDCS treatment 2 weeks following CSI did not result in any additive or potentializing effects when compared to a s-tDCS or a control group. Trial registration ClinicalTrials.gov, NCT03967574. Registered 30 May 2019 - Retrospectively registered.

Sign in / Sign up

Export Citation Format

Share Document